A New Drug BY002 for Relapsed Acute Leukemia with Genetic Changes
Part of Blood & lymphatic, Cancer clinical trials.
This phase 1 trial tests a new drug called BY002 for people with certain types of leukemia (AML, ALL, or MPAL) that have come back or not responded to treatment. It focuses on patients whose leukemia has a specific genetic change (KMT2A rearrangement or NPM1 mutation). The goal is to see if BY002 can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years or older.
- You have a confirmed diagnosis of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or mixed phenotype acute leukemia (MPAL).
- Your leukemia has come back after treatment or did not respond to at least one prior therapy.
- Your leukemia has a change in the KMT2A gene or NPM1 gene (this is preferred but not required).
- You are able to do daily activities with minimal help (ECOG performance status 0, 1, or 2).
- Your major organs (kidneys, liver, heart) are working well enough, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BEBT-908 plus chemotherapy for people with acute lymphoblastic leukemia that has a specific genetic change (MEF2D) or a certain immune type (pre-B). It's for patients whose leukemia is in remission but still has detectable tiny amounts of disease (MRD positive).
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
This trial tests a new drug called BT02 for people with blood cancers like leukemia, lymphoma, or multiple myeloma that have come back or stopped responding to treatment. The goal is to see if BT02 can help when other treatments haven't worked.
This trial tests a new drug (S243249) for people with acute leukemia that has come back or not responded to treatment. It focuses on those with specific gene changes (KMT2A, NUP98, or NPM1c) and aims to see if the drug is safe and effective.
This is a Phase 1 trial testing a new drug called BSB-2002 in patients with acute myeloid leukemia (AML) that has come back or stopped responding to previous treatments. The drug is designed specifically for patients whose cancer cells have a particular genetic change (NPM1 mutation) and may help control the cancer by activating the immune system.
This trial tests a new drug called PLM-102 in adults whose acute myeloid leukemia (a serious blood cancer) has come back or stopped responding to standard treatment. The goal is to see if PLM-102 can help patients whose cancer has proven difficult to control.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.